96 related articles for article (PubMed ID: 25438668)
1. Chemokine-receptor interactions: solving the puzzle, piece by piece.
Zhang L; LiWang PJ
Structure; 2014 Nov; 22(11):1550-2. PubMed ID: 25438668
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1.
Millard CJ; Ludeman JP; Canals M; Bridgford JL; Hinds MG; Clayton DJ; Christopoulos A; Payne RJ; Stone MJ
Structure; 2014 Nov; 22(11):1571-81. PubMed ID: 25450766
[TBL] [Abstract][Full Text] [Related]
3. Regulation of chemokine recognition by site-specific tyrosine sulfation of receptor peptides.
Simpson LS; Zhu JZ; Widlanski TS; Stone MJ
Chem Biol; 2009 Feb; 16(2):153-61. PubMed ID: 19246006
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine sulfation influences the chemokine binding selectivity of peptides derived from chemokine receptor CCR3.
Zhu JZ; Millard CJ; Ludeman JP; Simpson LS; Clayton DJ; Payne RJ; Widlanski TS; Stone MJ
Biochemistry; 2011 Mar; 50(9):1524-34. PubMed ID: 21235238
[TBL] [Abstract][Full Text] [Related]
5. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
6. CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation.
Miyagaki T; Sugaya M; Murakami T; Asano Y; Tada Y; Kadono T; Okochi H; Tamaki K; Sato S
Cancer Res; 2011 Mar; 71(6):2056-65. PubMed ID: 21406396
[TBL] [Abstract][Full Text] [Related]
7. CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs.
Park JY; Kang YW; Choi BY; Yang YC; Cho BP; Cho WG
J Recept Signal Transduct Res; 2017 Aug; 37(4):416-421. PubMed ID: 28279120
[TBL] [Abstract][Full Text] [Related]
8. Evolution of CCL11: genetic characterization in lagomorphs and evidence of positive and purifying selection in mammals.
Neves F; Abrantes J; Esteves PJ
Innate Immun; 2016 Jul; 22(5):336-43. PubMed ID: 27189425
[TBL] [Abstract][Full Text] [Related]
9. Homogeneous sulfopeptides and sulfoproteins: synthetic approaches and applications to characterize the effects of tyrosine sulfation on biochemical function.
Stone MJ; Payne RJ
Acc Chem Res; 2015 Aug; 48(8):2251-61. PubMed ID: 26196117
[TBL] [Abstract][Full Text] [Related]
10. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.
Manns J; Rieder S; Escher S; Eilers B; Forssmann WG; Elsner J; Forssmann U
Allergy; 2007 Jan; 62(1):17-24. PubMed ID: 17156337
[TBL] [Abstract][Full Text] [Related]
11. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Fujita H; Ohmatsu H; Kakinuma T; Kadono T; Tamaki K; Sato S
J Invest Dermatol; 2010 Sep; 130(9):2304-11. PubMed ID: 20505746
[TBL] [Abstract][Full Text] [Related]
12. Milligram production and biological activity characterization of the human chemokine receptor CCR3.
Wang M; Ge B; Li R; Wang X; Lao J; Huang F
PLoS One; 2013; 8(6):e65500. PubMed ID: 23755240
[TBL] [Abstract][Full Text] [Related]
13. Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis.
Mangieri D; Corradi D; Martorana D; Malerba G; Palmisano A; Libri I; Bartoli V; Carnevali ML; Goldoni M; Govoni P; Alinovi R; Buzio C; Vaglio A
Nephrol Dial Transplant; 2012 Oct; 27(10):3875-84. PubMed ID: 23114905
[TBL] [Abstract][Full Text] [Related]
14. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.
Zhu C; Xu B; Sun X; Zhu Q; Sui Y
Mol Neurobiol; 2017 Dec; 54(10):7964-7978. PubMed ID: 27878757
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent Cyclic Sulfopeptide Chemokine Inhibitors via Reprogrammed Genetic Code mRNA Display.
Johansen-Leete J; Passioura T; Foster SR; Bhusal RP; Ford DJ; Liu M; Jongkees SAK; Suga H; Stone MJ; Payne RJ
J Am Chem Soc; 2020 May; 142(20):9141-9146. PubMed ID: 32330017
[TBL] [Abstract][Full Text] [Related]
16. Upregulated expression of CCR3 in osteoarthritis and CCR3 mediated activation of fibroblast-like synoviocytes.
Chang X; Shen J; Yang H; Xu Y; Gao W; Wang J; Zhang H; He S
Cytokine; 2016 Jan; 77():211-9. PubMed ID: 26409848
[TBL] [Abstract][Full Text] [Related]
17. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
[TBL] [Abstract][Full Text] [Related]
18. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression.
Zhu F; Liu P; Li J; Zhang Y
Oncol Rep; 2014 May; 31(5):2049-54. PubMed ID: 24604010
[TBL] [Abstract][Full Text] [Related]
19. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner.
Sabroe I; Jorritsma A; Stubbs VE; Xanthou G; Jopling LA; Ponath PD; Williams TJ; Murphy PM; Pease JE
Eur J Immunol; 2005 Apr; 35(4):1301-10. PubMed ID: 15739168
[TBL] [Abstract][Full Text] [Related]
20. The polymorphisms of Eotaxin 1 and CCR3 genes influence on serum IgE, Eotaxin levels and mild asthmatic children in Taiwan.
Wang TN; Chiang W; Tseng HI; Chu YT; Chen WY; Shih NH; Ko YC
Allergy; 2007 Oct; 62(10):1125-30. PubMed ID: 17845580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
